Docoh
Loading...

PBLA Panbela Therapeutics

Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing disruptive therapeutics for patients with urgent unmet medical needs. The company's initial product candidate, SBP-101, is for the treatment of patients with metastatic pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer. Panbela Therapeutics, Inc. isdedicated to treating patients with pancreatic cancer and exploring SBP-101's potential for efficacy in combination with other agents and in treating other types of cancer.

Company profile

Ticker
PBLA
Exchange
Website
CEO
Michael Cullen
Employees
Incorporated
Location
Fiscal year end
Former names
Cimarron Medical, Inc., CIMARRON SOFTWARE INC, Sun BioPharma, Inc.
SEC CIK

PBLA stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

12 May 21
2 Aug 21
31 Dec 21
Quarter (USD)
Mar 21 Dec 20 Sep 20 Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 8.1M 8.1M 8.1M 8.1M 8.1M 8.1M
Cash burn (monthly) 308K (positive/no burn) 749.33K 579.08K 655K 391.58K
Cash used (since last report) 1.26M n/a 3.06M 2.37M 2.68M 1.6M
Cash remaining 6.84M n/a 5.04M 5.73M 5.42M 6.5M
Runway (months of cash) 22.2 n/a 6.7 9.9 8.3 16.6

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
25 May 21 Michael T. Cullen Common Stock Grant Aquire A No No 0 4,316 0 216,811
25 May 21 Michael T. Cullen Stock Option Common Stock Grant Aquire A No No 4.17 12,368 51.57K 12,368
25 May 21 Schaffer Paul W. Common Stock Grant Aquire A No No 0 4,316 0 166,671
25 May 21 Schaffer Paul W. Stock Option Common Stock Grant Aquire A No No 4.17 12,368 51.57K 12,368
25 May 21 Mathiesen Jeffrey S Common Stock Grant Aquire A No No 0 4,316 0 10,191
25 May 21 Mathiesen Jeffrey S Stock Option Common Stock Grant Aquire A No No 4.17 12,368 51.57K 12,368
25 May 21 Schemel Donald Robert Common Stock Grant Aquire A No No 0 4,316 0 96,619
25 May 21 Schemel Donald Robert Stock Option Common Stock Grant Aquire A No No 4.17 12,368 51.57K 12,368
25 May 21 Fratamico Arthur Common Stock Grant Aquire A No No 0 4,316 0 9,615
25 May 21 Fratamico Arthur Stock Option Common Stock Grant Aquire A No No 4.17 12,368 51.57K 12,368

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders
Current Prev Q Change
Total holders 0 0
Opened positions 0 0
Closed positions 0 5 EXIT
Increased positions 0 0
Reduced positions 0 0
13F shares
Current Prev Q Change
Total value 0 0
Total shares 0 0
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Largest transactions
Shares Bought/sold Change
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: acquire, Additionally, American, analyzed, ASCO, assessment, baseline, begun, blood, bone, CA, care, cell, checkpoint, chemotherapy, collaboration, conclusion, conference, conferred, country, cutoff, cycle, detachment, distribution, dosage, DSMB, efficacy, Eleven, entered, flat, GI, headcount, hereof, history, hold, India, ingredient, integral, justify, learn, light, Marker, marrow, Medicine, middle, monotherapy, neuropathy, Oncology, ophthalmologic, original, Panbela, PD, peripheral, preliminary, procure, regimen, remotely, responding, restarted, retinal, retinopathy, School, screening, separated, showed, social, Society, successfully, suggest, supplier, toxicity, visual, withhold, wrapping
Removed: Aid, amendment, amortization, amortized, annum, BioPharma, capitalized, charged, cohort, commenced, continuation, converted, DCR, deficit, discontinue, discount, executed, extend, hand, Institute, issuable, limitation, loan, mature, maturity, modification, monthly, payable, payroll, PDA, portion, PPP, program, Promising, promissory, Protection, PRs, reached, recommended, Relief, Security, Spring, Sun, therapy, unchanged, unpaid, unsecured, untreated, warrant, week